Company: NGVT
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001653477-25-000127
Chunk: 124

Company: Ingevity Corp
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 124
---
8.3 _______________(1) See Note 11 for more information. 

Goodwill impairment charge

Three and Nine Months Ended September 30, 2025 vs. 2024 

Goodwill impairment charge of zero and $183.8 million for the three and nine months ended September 30, 2025, respectively, within our Advanced Polymer Technologies reportable segment. Goodwill impairment charge of zero and $306.6 million for the three and nine months ended September 30, 2024, respectively, within our Performance Chemicals reportable segment. See Note 7 for more information.

Acquisition-related costs

Three and Nine Months Ended September 30, 2025 vs. 2024 

Acquisition-related (income) costs were zero for the three and nine months ended September 30, 2025, and $(0.1) million and zero for the three and nine months ended September 30, 2024, respectively. All charges relate to the integration of Ozark Materials into our Performance Chemicals reportable segment. 

Other (income) expense, net

Three and Nine Months Ended September 30, 2025 vs. 2024Three Months Ended September 30,Nine Months Ended September 30,In millions2025202420252024Foreign currency transaction (gain) loss $0.2 $1.0 $(1.3)$3.1 (Gain) loss on strategic investments (1)— 2.2 2.5 2.1 CEO severance charges— 4.8 — 4.8 Proxy contest charges (2)— — 8.2 — Portfolio review expenses (2)1.1 — 1.1 — Other (income) expense, net(0.1)(1.5)(1.0)(2.2)Total Other (income) expense, net$1.2 $6.5 $9.5 $7.8 _______________

(1) See Note 4 for more information.

(2) See Note 14 for more information.

39

Interest expense, net

Three and Nine Months Ended September 30, 2025 vs. 2024

Three Months Ended September 30,Nine Months Ended September 30,In millions2025202420252024Accounts receivable securitization (1)$1.3 $1.7 $3.1 $4